MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577429 | Name: Minoxidil tartrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Minoxidil is an antihypertensive and a vasodilator. Minoxidil, applied topically, is used for the treatment of hair loss. It is effective in helping promote hair growth in people with androgenic alopecia regardless of sex. Minoxidil is an adenosine 5'-triphosphate-sensitive potassium channel opener, causing hyperpolarization of cell membranes. Minoxidil stimulates prostaglandin E2 production by activating COX-1 and prostaglandin endoperoxide synthase-1 but inhibits prostacyclin production. minoxidil contains a nitric oxide moiety and may act as a nitric oxide agonist.

Chemical Structure

Minoxidil tartrate
Minoxidil tartrate
CAS#158473-55-3 (tartrate)

Theoretical Analysis

MedKoo Cat#: 577429

Name: Minoxidil tartrate

CAS#: 158473-55-3 (tartrate)

Chemical Formula: C13H21N5O7

Exact Mass: 359.1441

Molecular Weight: 359.34

Elemental Analysis: C, 43.45; H, 5.89; N, 19.49; O, 31.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
38304-91-5 (free base) 127228-87-9 (HCl) 210357-39-4 (sulfate) 158473-55-3 (tartrate)
Synonym
Minoxidil tartrate
IUPAC/Chemical Name
2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
InChi Key
SNCJAEVKCLODRY-LREBCSMRSA-N
InChi Code
InChI=1S/C9H15N5O.C4H6O6/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13;5-1(3(7)8)2(6)4(9)10/h6H,1-5,10H2,(H2,11,12);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
SMILES Code
Nc1cc(nc(N)n1=O)N2CCCCC2.O[C@H]([C@@H](O)C(=O)O)C(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 359.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kiratiwongwan R, Boonchai W, Kanokrungsee S. Allergic Contact Dermatitis to Topical Preparations Containing Minoxidil: A Systematic Review and Individual Participant Data Meta-Analysis. Dermatitis. 2024 Jun 17. doi: 10.1089/derm.2024.0092. Epub ahead of print. PMID: 38885151. 2: Williams KN, Olukoga CTY, Tosti A. Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review. Dermatol Ther (Heidelb). 2024 Jul;14(7):1709-1727. doi: 10.1007/s13555-024-01197-x. Epub 2024 Jun 11. PMID: 38861138; PMCID: PMC11264662. 3: Aledani EM, Kaur H, Kasapoglu M, Yadavalli R, Nawaz S, Althwanay A, Nath TS. Mesotherapy as a Promising Alternative to Minoxidil for Androgenetic Alopecia: A Systematic Review. Cureus. 2024 May 5;16(5):e59705. doi: 10.7759/cureus.59705. PMID: 38841017; PMCID: PMC11152360. 4: Raval RS, Nohria A, Desai D, Mourtzanakis K, Buontempo M, Shapiro J, Lo Sicco K. The use of minoxidil in the treatment of alopecia areata: A systematic review. J Am Acad Dermatol. 2024 May 23:S0190-9622(24)00796-5. doi: 10.1016/j.jaad.2024.05.037. Epub ahead of print. PMID: 38796079. 5: Ly N, McClure EM, Hordinsky MK, Farah RS, Park SY. Safety and Efficacy of Minoxidil Treatment in Scarring Alopecia: A Scoping Review. J Drugs Dermatol. 2024 Mar 1;23(3):146-151. doi: 10.36849/jdd.7743. PMID: 38443124. 6: Darchini-Maragheh E, Rees H, Moussa A, Bokhari L, Jones L, Sinclair R. Role of systemic minoxidil in the treatment of alopecia areata: A scoping review to direct future research. J Am Acad Dermatol. 2024 Jun;90(6):1304-1306. doi: 10.1016/j.jaad.2024.02.031. Epub 2024 Feb 28. PMID: 38423467. 7: Gupta AK, Talukder M, Shemer A. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. Expert Opin Pharmacother. 2024 Feb;25(2):139-147. doi: 10.1080/14656566.2024.2314087. Epub 2024 Feb 6. PMID: 38315101. 8: Godse K, De A, Vedamurthy M, Shankar DSK, Shah B, Girdhar M, Bhat R, Ganjoo A, Tahiliani S, Patil A. Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts. Int J Trichology. 2023 May-Jun;15(3):91-97. doi: 10.4103/ijt.ijt_70_23. Epub 2023 Dec 1. PMID: 38179013; PMCID: PMC10763725. 9: Gupta AK, Wang T, Bamimore MA, Polla Ravi S, Talukder M. Relative Effects of Minoxidil 5%, Platelet-Rich Plasma, and Microneedling in Pattern Hair Loss: A Systematic Review and Network Meta-Analysis. Skin Appendage Disord. 2023 Dec;9(6):397-406. doi: 10.1159/000534196. Epub 2023 Oct 27. PMID: 38058547; PMCID: PMC10697753. 10: Udare S, Baruah A, Mathur A, Dayananda TR, Jain K, Puhan MR, Bajaj P, Sharma R, Gamit SR, Ramesh V, Venugopal V, Karthik V, Neena Gala MY, Muchhala S, Mane A. Positioning of Low Alcohol or Alcohol-Free Minoxidil Formulation for the Management of Androgenetic Alopecia: Indian Perspective. Int J Trichology. 2023 Jan-Feb;15(1):13-17. doi: 10.4103/ijt.ijt_54_22. Epub 2023 Apr 19. PMID: 37305189; PMCID: PMC10251296. 11: Tavakoli MR, Faraji M, Sam S, Ghasempour A, Rezaei M, Langarizadeh MA, Karami-Mohajeri S. Erectile dysfunction from mechanisms to medicines with a focus on the application of topical Minoxidil. Sex Med Rev. 2023 Apr 3;11(2):114-123. doi: 10.1093/sxmrev/qead001. PMID: 36857310. 12: Zhang J, Lin P, Lin H, Ma C, Hu Y, Wang Y, Zhang Y. Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2023 Feb 17;38(1):74. doi: 10.1007/s10103-023-03734-0. PMID: 36800063. 13: Ramírez-Marín HA, Tosti A. Role of Oral Minoxidil in Patterned Hair Loss. Indian Dermatol Online J. 2022 Oct 12;13(6):729-733. doi: 10.4103/idoj.idoj_246_22. PMID: 36386734; PMCID: PMC9650732. 14: Saleem K, Siddiqui B, Ur Rehman A, Taqi MM, Ahmed N. Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. AAPS PharmSciTech. 2022 Nov 1;23(8):292. doi: 10.1208/s12249-022-02444-0. PMID: 36319878. 15: Modha JD, Pathania YS. Comprehensive review of oral minoxidil in alopecia. J Cosmet Dermatol. 2022 Nov;21(11):5527-5531. doi: 10.1111/jocd.15324. Epub 2022 Sep 20. PMID: 36065675. 16: Pietrauszka K, Bergler-Czop B. Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatol Alergol. 2022 Jun;39(3):472-478. doi: 10.5114/ada.2020.99947. Epub 2020 Oct 16. PMID: 35950120; PMCID: PMC9326921. 17: Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Nov;33(7):2946-2962. doi: 10.1080/09546634.2022.2109567. Epub 2022 Aug 15. PMID: 35920739. 18: Singh S, Patil A, Kianfar N, Waśkiel-Burnat A, Rudnicka L, Sinclair R, Goldust M. Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022 Nov;47(11):1951-1955. doi: 10.1111/ced.15338. PMID: 35881665. 19: Nilforoushzadeh MA, Heidari-Kharaji M, Torkamaniha E, Sadeghi S, Seirafianpour F, Yekaninejad MS, Behrangi E, Roohaninasab M, Amini Z, Goodarzi A. The first study on combined carboxytherapy and minoxidil 20% in the treatment of Lichen planopilaris: A case series and literature review. J Cosmet Dermatol. 2022 Nov;21(11):6453-6455. doi: 10.1111/jocd.15079. Epub 2022 Jun 2. PMID: 35559595. 20: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Minoxidil. 2022 Mar 21. PMID: 30000091.